Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

119.50 +1.52 (+1.29%)
Streaming Delayed Price Updated: 12:43 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
63 64 Next >
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
The Analyst Verdict: Gilead Sciences In The Eyes Of 14 Experts
 
Via Benzinga
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad... 
Via StockStory
Topics Artificial Intelligence
The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI)
Via The Motley Fool
Topics Artificial Intelligence
Gilead Sciences's Options: A Look at What the Big Money is Thinking
 
Via Benzinga
P/E Ratio Insights for Gilead Sciences
 
Via Benzinga
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
 
Via Benzinga
Gilead Sciences Unusual Options Activity
 
Via Benzinga
1 Value Stock with Exciting Potential and 2 to Ignore
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
Best And Worst Performing S&P 500 Stocks Since Trump's Election Win
Financial markets volatile since Trump's 2024 election, some companies surged like Palantir while others struggled such as First Solar. 
Via Benzinga
Topics Government Stocks
Salesforce Earnings Top Views. Software Stock Falls On Weak Revenue Outlook.
Salesforce stock fell after the company's revenue guidance for fiscal 2026 came in below expectations, despite the ramp of new AI products. 
Via Investor's Business Daily
Topics Artificial Intelligence
European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
How Is The Market Feeling About Gilead Sciences?
 
Via Benzinga
16 Analysts Have This To Say About Gilead Sciences
 
Via Benzinga
What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know. 
Via StockStory
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer 
Via MarketBeat
Topics Death
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?
JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management. 
Via Stocktwits
Large Cap Biopharmaceutical Metrics And Performance Q1 2025
Tariffs could have big impact on earnings in 2025. 
Via Talk Markets
Topics Stocks / Equities
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
From Gilead Sciences, Inc.
Via Business Wire
This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
 
Via Benzinga
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know. 
Via StockStory
Bullish Setups
You know things are bad when I stoop to offering some bullish setups, but that’s just where we’re at right now. 
Via Talk Markets
Topics Stocks / Equities
Robinhood, Gilead Sciences, Crocs, Lincoln Electric, HubSpot, GE HealthCare And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Moderna (MRNA) Q4 Earnings Report Preview: What To Look For
Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market open. Here’s what to expect. 
Via StockStory
Top S&P500 movers in Wednesday's session
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025. 
Via Benzinga
These S&P500 stocks have an unusual volume in today's session
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below. 
Via Chartmill
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
63 64 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.